On June 26, 2024, the FDA issued its draft guidance on Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies. This guidance is a key initiative aimed at enhancing the inclusion of diverse populations in clinical trials.
Join Novotech and an expert panel, including a former FDA senior official, for a discussion on the FDA’s draft guidance. The panel will provide actionable insights to enhance the enrollment of underrepresented populations in your clinical trials.
The discussion will feature insights from leading experts in the field:
- Isaac Rodriguez-Chavez (Former FDA senior official, Consultant, Scientific, Clinical & Regulatory Affairs)
- Chardae Rodgers-Gamble (CEO, CR Clinical)
- Danielle Mitchell (Founder, Black Women in Clinical Research)
- Sarah Anderson (Oncology Strategy Director, Novotech)
- Judith Ng-Cashin (Chief Medical Officer, Novotech)
Key topics include:
- Purpose and goals of the FDA draft guidance.
- Critical components of FDA diversity action plans for both small and large global clinical trials.
- Recommendations on how and when to integrate diversity plans into your existing operational frameworks.
- Solutions to overcome site selection and recruitment challenges.
This is an opportunity to gain expert insights from industry leaders and ensure your clinical trials align with the new FDA diversity requirements.
Register for the webinar here: https://event.on24.com/wcc/r/4666007/C5B008BF309E035C12AEA0D9A314C5CE
Unable to attend? Register to receive access to the on-demand recording.